Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
By J. Hicks, J. Bishop, K. Sangkuhl, Daniel J. Müller, Yuan Ji, SG Leckband, J. S. Leeder, Rebecca L. Graham, DL Chiulli, A. Llerena and 6 more. Clinical pharmacology and therapy, 2015
886 citations recorded by the source corpus.
Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).
Subfields: Molecular Biology, Pharmacology
View Paper: https://www.semanticscholar.org/paper/84c755ac0c7513847249a3472afefb445b098470
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pharmacology
Citations in the corpus
- Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder (2016, background): “Pharmacogenetic testing for CYP enzymes is now available in many regions, and comprehensive recommendations for antidepressants have been suggested by the Clinical Pharmacogenetics Implementation Consortium (CPIC).(77) Since large-scale RCTs to examine the utility of pharmacogenetic tests are still ”
- Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (2017, methodology): “, CYP2D6*3-*6).(2,3) Because CYP2D6 is subject to deletions or duplications, many clinical laboratories also report copy number.”